131 related articles for article (PubMed ID: 32633354)
1. LncRNA MT1JP inhibits the malignant progression of hepatocellular carcinoma through regulating AKT.
Wu JH; Xu K; Liu JH; Du LL; Li XS; Su YM; Liu JC
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6647-6656. PubMed ID: 32633354
[TBL] [Abstract][Full Text] [Related]
2. MIIP inhibits malignant progression of hepatocellular carcinoma through regulating AKT.
Fang J; Chen YL; Yao HB; Peng SS; Yang P; Ding ZY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2335-2346. PubMed ID: 32196585
[TBL] [Abstract][Full Text] [Related]
3. STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway.
Wu JZ; Jiang N; Lin JM; Liu X
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2977-2985. PubMed ID: 32271415
[TBL] [Abstract][Full Text] [Related]
4. LncRNA TP73-AS1 promotes malignant progression of hepatoma by regulating microRNA-103.
Ma CX; Gao WC; Tian L
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4713-4722. PubMed ID: 31210297
[TBL] [Abstract][Full Text] [Related]
5. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway.
Liu FH; Cui YP; He YK; Shu RH
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557
[TBL] [Abstract][Full Text] [Related]
6. LncRNA HOTAIRM1 inhibits the progression of hepatocellular carcinoma by inhibiting the Wnt signaling pathway.
Zhang Y; Mi L; Xuan Y; Gao C; Wang YH; Ming HX; Liu J
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4861-4868. PubMed ID: 30070317
[TBL] [Abstract][Full Text] [Related]
7. LncRNA MINCR promotes the development of liver cancer by regulating microRNA-107/β-catenin.
Li H; Yuan R; Wang H; Li C; Wei J
J BUON; 2020; 25(2):972-980. PubMed ID: 32521894
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-30a-3p inhibits malignant progression of hepatocellular carcinoma through regulating IGF1.
Wei YY; Ren TL
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12144-12152. PubMed ID: 33336732
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-328-3p inhibits malignant progression of hepatocellular carcinoma by regulating MMP-9 level.
Li JZ; Li J; Liu BZ
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9331-9340. PubMed ID: 31773692
[TBL] [Abstract][Full Text] [Related]
10. LncRNA H19 promotes the development of hepatitis B related hepatocellular carcinoma through regulating microRNA-22 via EMT pathway.
Li L; Han T; Liu K; Lei CG; Wang ZC; Shi GJ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5392-5401. PubMed ID: 31298392
[TBL] [Abstract][Full Text] [Related]
11. miRNA-217 inhibits proliferation of hepatocellular carcinoma cells by regulating KLF5.
Gao W; Lu YX; Wang F; Sun J; Bian JX; Wu HY
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7874-7883. PubMed ID: 31599412
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway.
Wang X; Dong K; Jin Q; Ma Y; Yin S; Wang S
J Cell Biochem; 2019 Apr; 120(4):6781-6788. PubMed ID: 30382631
[TBL] [Abstract][Full Text] [Related]
13. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
14. LncRNA TRERNA1 promotes malignant progression of NSCLC through targeting FOXL1.
Luo DB; Lv HB; Sun XH; Wang Y; Chu JH; Salai AL
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1233-1242. PubMed ID: 32096153
[TBL] [Abstract][Full Text] [Related]
15. LncRNA 00152 promotes the development of hepatocellular carcinoma by activating JAK2/STAT3 pathway.
Li SJ; Sui MH; Sun ZX; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1038-1046. PubMed ID: 30779070
[TBL] [Abstract][Full Text] [Related]
16. LncRNA DCST1-AS1 accelerates the proliferation, metastasis and autophagy of hepatocellular carcinoma cell by AKT/mTOR signaling pathways.
Li J; Zhai DS; Huang Q; Chen HL; Zhang Z; Tan QF
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6091-6104. PubMed ID: 31364110
[TBL] [Abstract][Full Text] [Related]
17. LINC00963 promotes hepatocellular carcinoma progression by activating PI3K/AKT pathway.
Wu JH; Tian XY; An QM; Guan XY; Hao CY
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1645-1652. PubMed ID: 29630107
[TBL] [Abstract][Full Text] [Related]
18. LncRNA RUNX1-IT1 inhibits proliferation and promotes apoptosis of hepatocellular carcinoma by regulating MAPK pathways.
Yan PH; Wang L; Chen H; Yu FQ; Guo L; Liu Y; Zhang WJ; Bai YL
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8287-8294. PubMed ID: 31646558
[TBL] [Abstract][Full Text] [Related]
19. lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway.
Pan W; Li W; Zhao J; Huang Z; Zhao J; Chen S; Wang C; Xue Y; Huang F; Fang Q; Wang J; Brand D; Zheng SG
Mol Oncol; 2019 Oct; 13(10):2246-2258. PubMed ID: 31368655
[TBL] [Abstract][Full Text] [Related]
20. lncRNA MT1JP-overexpression abolishes the silencing of PTEN by miR-32 in hepatocellular carcinoma.
Zhang S; Xu J; Chen Q; Zhang F; Wang H; Guo H
Oncol Lett; 2021 Aug; 22(2):604. PubMed ID: 34188706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]